Nausea: Nausea is one of the most commonly reported side effects of GLP-1 medications, particularly during the initial stages of treatment
Research published in Diabetes has shown that GLP-1 receptor activation in the central nervous system directly reduces food intake (Turton et al., 1996) Slowed gastric emptying GLP-1 delays how quickly food moves from the stomach into the small intestine, prolonging satiety after meals Enhanced insulin secretion GLP-1 stimulates glucose-dependent insulin release from pancreatic beta cells, helping regulate blood sugar without causing hypoglycemia Glucagon suppression Paradoxically, while retatrutide also activates the glucagon receptor directly, GLP-1 pathway activation suppresses inappropriate glucagon release after meals, helping stabilize postprandial blood sugar This is the same pathway that semaglutide targets, and it accounts for much of the appetite suppression that weight loss medications produce
For example, improvements in blood sugar control, blood pressure, or sleep apnea symptoms may reverse as weight is regained
Rheumatoid arthritis, cardiovascular disease, neurodegeneration, and even hair loss are all being investigated in the context of GLP-1 receptor signaling
We also do not require long-term contracts, allowing you to move forward with confidence and clarity in your care plan
